September 2023 FDA Watch
More multiplex COVID-19 combination tests emerge from premarket authorization pipeline.
More multiplex COVID-19 combination tests emerge from premarket authorization pipeline.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
An overview of the layoffs announced by major lab diagnostic companies in the first half of 2023 and the key trends.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
In the first half of this year, US companies have cut the second-highest total of jobs since 2009, according to a recent report.